The hospital launched their endometriosis Focal One program following the acquisition of the system with the intention of utilizing it for treating both deep infiltrating endometriosis and prostate cancer. This launch is part of FocalTherics’ broader expanded launch strategy, with more than 10 hospitals in the Company’s active clinical training pathway across Europe, the United Kingdom, and Latin America.

The Focal One procedures at Toulouse University Hospital were performed by Professor Elodie Chantalat, Head of the Department of Gynecology. Professor Gil Dubernard, Head of the Gynecologic and Obstetric Department at Croix-Rousse University Hospital in Lyon, who pioneered the use of Focal One for treating deep infiltrating endometriosis, served as proctor for these initial procedures.

Approximately 38 million women worldwide suffer from deep infiltrating endometriosis, a severe form of the disease that invades organs surrounding the uterus.1 It is characterized by chronic pelvic pain, painful bowel symptoms, and significant impairment in quality of life. Treatment has historically been limited to complex surgery associated with potential morbidity and lengthy recovery periods. Research indicates that 91% of women with the condition would prefer a non-surgical alternative that minimizes associated complications and underscores the unmet need that the Focal One Robotic HIFU system is positioned to address.2

Focal One Robotic HIFU utilizes imaging and high-intensity focused ultrasound technology to precisely target and ablate endometriosis lesions on the bowel and rectum without incisions or surgery. The treatment is performed under real-time image guidance and is designed to minimize impact on surrounding healthy structures.